BIO.News Newsletter

A look at what’s driving vaccine hesitancy in this critical moment for several respiratory viruses—plus, new developments in CRISPR that could enable more efficient medical treatment delivery in living humans. (464 words, 2 minutes, 19 seconds)

Top legal experts explain why laws like Bayh-Dole and Section 1498 should not be used to control prices, and Novavax becomes the third updated COVID shot cleared for use in the U.S. as cases surge. (553 words, 2 minutes, 19 seconds)

Good news out of the D.C. District Court, which struck down a rule that allowed insurers and PBMs to pocket copay assistance intended for patients. We have details, plus today’s new episode of the I am BIO Podcast explores why we need women leadership in biotech and a lot more news.  (754 words, 3 minutes, 46 seconds)

A very quick update on what’s been happening on Capitol Hill and why it matters to biotech—plus, meet BIO’s new agriculture and environment working groups. (556 words, 2 minutes, 46 seconds)

While we wait to see what happens with government funding before tomorrow’s deadline, we have news on a new PBM transparency bill, a new collaboration to help patients enroll in clinical trials, and a win for patients with Pompe disease. (590 words, 2 minutes, 57 seconds)

A new poll shows voters like the Bayh-Dole Act—but not when it’s used for price controls. Plus, catch up on what’s been happening with PBMs and what we’re watching during World Alzheimer’s Month. (545 words, 2 minutes, 43 seconds)

We take a deep dive into ICER’s updated treatment assessment—plus, how biotech is making crops more resilient in the face of an increasingly harsher climate. (609 words, 3 minutes, 2 seconds)

Several new studies highlight the growing problem of PBMs—plus, Bio.News has an exclusive look at the growing “biotech sisterhood” and how women CEOs are helping women colleagues and patients. (550 words, 2 minutes, 45 seconds)

Starting a new week with another option to protect infants from RSV and BIO’s MOU with Vietnam’s state pharma company. (513 words, 2 minutes, 33 seconds)

Ending a busy week with a recap of John Crowley’s testimony on Capitol Hill yesterday and a look at the problems with alternative funding programs—plus, what companies and investors are saying about the BIO Investor Forum. (508 words, 2 minutes, 32 seconds)